ArticleJACC. Asia2026
Prognostic Value of Left Ventricular Kinetic Energy for Predicting Major Adverse Events in Hypertrophic Cardiomyopathy.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophied left ventricle (LV) in hypertrophic cardiomyopathy (HCM) alters blood flow hemodynamics.
objectivesThe authors aimed to evaluate whether 4-dimensional (4D) flow cardiac magnetic resonance (CMR) parameters can predict major adverse cardiac events (MACE) in HCM.
methodsThis retrospective study included 165 adult HCM patients (mean age 51 years; 115 were male), and 115 normal control subjects with similar age and sex (INITIATE registry). All subjects underwent cine and 4D flow CMR, with LV ejection fraction and maximal left atrial volume calculated from cine images, and LV flow components and kinetic energy (KE) computed from 4D flow CMR. MACE included sudden cardiac death (SCD), aborted SCD, heart failure hospitalization, and stroke.
resultsDuring follow-up (median: 38 months; Q1-Q3: 23-48 months), 30 patients (18%) experienced MACE. Compared with control subjects, HCM patients had reduced LV global KEi
conclusionsWe found that 4D flow-derived LV global KEi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.